Blade(BLDE) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenue of $66.8 million, driven by logistics growth, with organic growth of 35.3% to $49.2 million compared to $36.4 million in the prior year [21][24] - Full year 2025 revenue and adjusted EBITDA were $197.1 million and $14.1 million respectively, both exceeding the high end of guidance [21][24] - Adjusted EBITDA rose to $7 million in Q4 2025, up from $1.1 million in the prior year period [25] Business Line Data and Key Metrics Changes - Logistics revenue in Q4 2025 was $49.2 million, reflecting a 35.3% organic growth [21][24] - Clinical revenue was $17.6 million in Q4 2025, significantly up from $2.8 million in Q3 2025, attributed to the Keystone acquisition [22][23] - Transplant clinical revenue was $7.8 million in Q4 2025, while other clinical revenue was $9.8 million [23][24] Market Data and Key Metrics Changes - Approximately 20% of the company's revenue is generated from Organ Procurement Organizations (OPOs), with Tier One OPO customers representing 2.4 times the revenue of Tier Three OPOs [10] - The company is well-positioned to benefit from regulatory changes incentivizing the pursuit of medically complex organs, particularly from DCD donors [9][10] Company Strategy and Development Direction - The company is focusing on acquisitions of smaller businesses to accelerate growth and expand geographically [5][6] - The M&A strategy aims for an annualized adjusted EBITDA growth of at least 30% in the coming years [6][14] - The company is also exploring opportunities to leverage existing assets for adjacent offerings, such as radiopharmaceuticals [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the future, raising guidance for 2026 revenue to $260 million-$275 million and adjusted EBITDA to $29 million-$33 million [27] - The company noted that while there was a soft January for the industry, strong daily logistics trips and clinical cases have continued into 2026 [28] - Management is optimistic about the integration of the organ transplant platform and the positive feedback from customers [30] Other Important Information - The company ended the year with approximately $61 million in cash and short-term investments and no debt [27] - Adjusted SG&A rose to $8.9 million in Q4 2025, reflecting a full quarter of Keystone SG&A [25] Q&A Session Summary Question: Update on continuous distribution policy - Management stated that continuous distribution is still the goal for all organs, with lungs already transitioned. The timeline for hearts and livers is uncertain due to regulatory focus on other issues [32][34] Question: Which part of the service has the highest value and margin? - Management indicated that transplant clinical business has slightly higher profit margins than non-transplant clinical business, with an integrated offering driving growth [36][38] Question: Acquisition pipeline and adjacent offerings - The company plans to announce acquisitions as they close and is focused on product servicing to increase scale and national footprint [41][42] Question: Impact of weather on operations - Unusual severe weather in the Northeast affected operations, but management remains confident in overall performance and guidance [70][71] Question: Impact of higher oil prices - Higher fuel prices will result in increased costs for customers but will not impact the company's cost structure as surcharges are negotiated [73][74]